期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 14, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13045-021-01147-6
关键词
Anti-angiogenesis; Endogenous angiogenic growth factor inhibitor; KAI1 (CD82); Pericyte
资金
- Korea Health Technology R&D Project through KHIDI, Republic of Korea [HI14C1277, HI-17 C-2085]
- Basic Science Research Program through the National Research Foundation of Korea [2020R1I1A3069714]
- Pusan National University
- National Research Foundation of Korea [2020R1I1A3069714] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
KAI1, mainly expressed in pericytes, is a novel endogenous anti-angiogenic factor that inhibits angiogenesis through inducing LIF and directly binding to VEGF and PDGF. Supplementation of KAI1 significantly inhibits tumor angiogenesis and growth, and a peptide derived from it has shown anti-angiogenic effects in vivo.
Background Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism and clinical significance. Methods Herein, we found Kai1 knockout mice showed significantly enhanced angiogenesis. Then, we investigated the anti-angiogenic roll of Kai1 in vitro and in vivo. Results KAI1 was mainly expressed in pericytes rather than in endothelial cells. It localized at the membrane surface after palmitoylation by zDHHC4 enzyme and induced LIF through the Src/p53 pathway. LIF released from pericytes in turn suppressed angiogenic factors in endothelial cells as well as in pericytes themselves, leading to inhibition of angiogenesis. Interestingly, KAI1 had another mechanism to inhibit angiogenesis: It directly bound to VEGF and PDGF and inhibited activation of their receptors. In the two different in vivo cancer models, KAI1 supplementation significantly inhibited tumor angiogenesis and growth. A peptide derived from the large extracellular loop of KAI1 has been shown to have anti-angiogenic effects to block the progression of breast cancer and retinal neovascularization in vivo. Conclusions KAI1 from PC is a novel molecular regulator that counterbalances the effect of angiogenic factors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据